Maine LD 422: An Act To Improve Access to Treatments for Lyme Disease

LD 422 (subjects: DISEASES , LYME DISEASE )

Official bill page at mainelegislature.org: http://www.mainelegislature.org/legis/bills/display_ps.asp?ld=422&PID=1456&snum=127


Sponsors | Actions | Bill Text & Amendments | Patterns of Support | In The News


Sponsors

Principal Sponsor: Rep. Deborah Sanderson of Chelsea: (R – District 88) — e-mail | Twitter | Facebook

9 Cosponsors:

Actions

Chamber

Action
2/12/2015 House Committee on Labor, Commerce, Research and Economic Development suggested and ordered printed.
The Bill was REFERRED to the Committee on LABOR, COMMERCE, RESEARCH AND ECONOMIC DEVELOPMENT.
Sent for concurrence. ORDERED SENT FORTHWITH.
2/12/2015 Senate On motion by Senator Volk of Cumberland, REFERRED to the Committee on Labor, Commerce, Research and Economic Development, in concurrence.
5/29/2015 House Reports READ.
On motion of Representative HERBIG of Belfast, the Majority Ought to Pass as Amended Report was ACCEPTED.
ROLL CALL NO. 115
(Yeas 106 – Nays 34 – Absent 11 – Excused 0)
The Bill was READ ONCE.
Committee Amendment “A” (H-216) was READ and ADOPTED.
Under suspension of the rules, the Bill was given its SECOND READING without REFERENCE to the Committee on Bills in the Second Reading.
The Bill was PASSED TO BE ENGROSSED as Amended by Committee Amendment “A” (H-216).
Sent for concurrence. ORDERED SENT FORTHWITH.
6/1/2015 Senate Reports READ
On motion by Senator VOLK of Cumberland Tabled until Later in Today’s Session, pending ACCEPTANCE OF EITHER REPORT
6/1/2015 Senate Unfinished Business
6/2/2015 Senate Unfinished Business
6/3/2015 Senate Unfinished Business
6/4/2015 Senate Unfinished Business
6/5/2015 Senate Unfinished Business
6/8/2015 Senate Taken from the table by the President ProTem
On motion by Senator VOLK of Cumberland the Minority Ought to Pass As Amended by Committee Amendment “B” (H-217) report, in NON-CONCURRENCE. FAILED
Roll Call Ordered Roll Call # 159 10 Yeas – 25 Nays- 0 Excused – 0 Absent
Subsequently, Majority Ought to Pass As Amended by Committee Amendment “A” (H-216) Report ACCEPTED , in concurrence.
READ ONCE
Committee Amendment “A” (H-216) READ and ADOPTED , in CONCURRENCE.
Under suspension of the Rules, READ A SECOND TIME and PASSED TO BE ENGROSSED AS AMENDED by Committee Amendment “A” (H-216) , in CONCURRENCE.
Ordered sent down forthwith.
6/10/2015 House PASSED TO BE ENACTED.
Sent for concurrence. ORDERED SENT FORTHWITH.
6/10/2015 Senate PASSED TO BE ENACTED, in concurrence.

Bill Text & Amendments

Important Note: The bill text below presents L.D. 422 as originally introduced. L.D. 422 was changed by the legislature through amendment. To understand the impact of this legislation in proper context, be sure to read adopted amendment text, available here: C-A (H-216) .

An Act To Improve Access to Treatments for Lyme Disease

Be it enacted by the People of the State of Maine as follows:

Sec. 1. 32 MRSA 3282-B is enacted to read:

3282-B. Lyme disease treatment

1. Definitions. As used in this section, unless the context otherwise indicates, the following terms have the following meanings.

A. “Clinical diagnosis” means a diagnosis that is based on knowledge obtained through medical history and physical examination of a patient alone or in conjunction with testing that provides supportive data for the diagnosis.
B. “Long-term antibiotic therapy” means the prolonged administration of oral, intramuscular or intravenous antibiotics for a period greater than 28 days.
C. “Lyme disease” is a condition caused by an infection of the bacterium Borrelia burgdorferi transmitted to humans through the bite of infected blacklegged ticks.

2. Lyme disease treatment. The board may not suspend or revoke a license or discipline a licensee under this chapter because the licensee prescribed, administered or dispensed long-term antibiotic therapy pursuant to a treatment plan for a patient clinically diagnosed with acute, persistent or chronic Lyme disease if:

A. The clinical diagnosis and treatment plan were made considering the patient’s individual circumstance and pursuant to a treatment guideline recommended by the United States Department of Health and Human Services, Centers for Disease Control and Prevention; or
B. The licensee used the licensee’s best judgment with respect to the particular patient or special clinical situation in the prescription, administration and dispensation of the long-term antibiotic therapy.

SUMMARY

This bill prohibits the Board of Licensure in Medicine from disciplining a physician or revoking or suspending a physician’s license for prescribing, administering or dispensing long-term antibiotic therapy to a patient with acute, persistent or chronic Lyme disease if the therapy was pursuant to a treatment plan recommended by the United States Department of Health and Human Services, Centers for Disease Control and Prevention that considered the patient’s individual circumstance or was in the best judgment of the physician with respect to the particular patient or special clinical situation.

Patterns of Support

Pattern of Cosponsorship by Region:

Pattern of Cosponsorship by Gender:

Pattern of Cosponsorship by Party:

Pattern of Cosponsorship by Campaign Finance Classification:

Note: Maine Clean Elections Act (MCEA) Qualified candidates only accept a small dollar value of initial contributions early in their campaigns, pledge not to accept further campaign contributions from private sources, and receive public funding for their campaigns. MCEA Non-Qualified candidates choose not to obtain public funding and instead are free to accept campaign contributions from individuals, party committees, political action committees and business sources.


In The News…

Recent news stories featuring LD 422:


This information about LD 422 was last updated on 2016-05-12.
The Open Maine Politics website is in a beta release and results should not be taken as definitive. Please visit the official website of the Maine State Legislature for entirely verifiable information.

Be the first to comment on "Maine LD 422: An Act To Improve Access to Treatments for Lyme Disease"

Leave a comment

Democracy thrives on participation; please share your thoughts!
Your email address will not be published. Required fields are marked *

Your email address will not be published.


*